Internal medicine, VU University medical center, Medical Microbiology and Infection Prevention, AII - Infectious diseases, CCA - Cancer biology and immunology, AII - Inflammatory diseases, AMS - Rehabilitation & Development, APH - Quality of Care, Pulmonary medicine, ACS - Pulmonary hypertension & thrombosis, Ethics, Law & Medical humanities, APH - Methodology, Midwifery Science, Amsterdam Reproduction & Development (AR&D), Infectious diseases, APH - Digital Health, APH - Personalized Medicine, APH - Aging & Later Life, APH - Global Health, Global Health, APH - Health Behaviors & Chronic Diseases, Center of Experimental and Molecular Medicine, General Internal Medicine, AII - Cancer immunology, Landsteiner Laboratory, Cardiology, ACS - Heart failure & arrhythmias, Obstetrics and Gynaecology, ARD - Amsterdam Reproduction and Development, Microbes in Health and Disease (MHD), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Global Health in the Global South (GHiGS), Institut de Recherche pour le Développement (IRD)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
المصدر:
Journal of Hepatology, 78(5), 947-957. Elsevier Journal of hepatology, 78(5), 947-957. Elsevier Journal of Hepatology, 78, 5, pp. 947-957 the Swiss HIV Cohort Study, EuroSIDA, ATHENA Observational Cohort Study & ANRS CO3 Aquitaine Cohort 2023, ' External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection ', Journal of Hepatology, vol. 78, no. 5, pp. 947-957 . https://doi.org/10.1016/j.jhep.2022.12.029Test Journal of Hepatology, 78(5), 947-957. ELSEVIER SCIENCE BV Journal of Hepatology Journal of Hepatology, 2023, 78 (5), pp.947-957. ⟨10.1016/j.jhep.2022.12.029⟩ Surial, Bernard; Ramírez Mena, Adrià; Roumet, Marie; Limacher, Andreas; Smit, Colette; Leleux, Olivier; Mocroft, Amanda; van der Valk, Marc; Bonnet, Fabrice; Peters, Lars; Rockstroh, Jürgen K; Günthard, Huldrych F; Berzigotti, Annalisa; Rauch, Andri; Wandeler, Gilles (2023). External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. Journal of hepatology, 78(5), pp. 947-957. Elsevier 10.1016/j.jhep.2022.12.029 <http://dx.doi.org/10.1016/j.jhep.2022.12.029Test>
Background & Aims: HBV coinfection is common among people living with HIV (PLWH) and is the most important cause of hepatocellular carcinoma (HCC). While risk prediction tools for HCC have been validated in patients with HBV monoinfection, they have not been evaluated in PLWH. Thus, we performed an external validation of PAGE-B in people with HIV/HBV coinfection.Methods: We included data on PLWH from four European cohorts who were positive for HBsAg and did not have HCC before starting tenofovir. We estimated the predictive performance of PAGE-B for HCC occurrence over 15 years in patients receiving tenofovir-containing antiretroviral therapy. Model discrimination was assessed after multiple imputation using Cox regression with the prognostic index as a covariate, and by calculating Harrell's c-index. Calibration was assessed by comparing our cumulative incidence with the PAGE-B derivation study using Kaplan-Meier curves.Results: In total, 2,963 individuals with HIV/HBV coinfection on tenofovir-containing antiretroviral therapy were included. PAGE-B was Conclusions: For individuals with HIV/HBV coinfection, PAGE-B is a valid tool to determine the need for HCC screening. Impact and implications: Chronic HBV infection is the most important cause of hepatocellular carcinoma (HCC) among people living with HIV. Valid risk prediction may enable better targeting of HCC screening efforts to high-risk individuals. We aimed to validate PAGE-B, a risk prediction tool that is based on age, sex, and platelets, in 2,963 individuals with HIV/HBV coinfection who received tenofovir-containing antiretroviral therapy. In the present study, PAGE-B showed good discrimination, adequate calibration, and a cut-off of
